Salkind Gene 4
4 · Mobiquity Technologies, Inc. · Filed Nov 9, 2023
Insider Transaction Report
Form 4
Salkind Gene
Director10% Owner
Transactions
- Award
Preferred Stock
2023-11-07+300,789→ 3,103,990 totalExercise: $5.00From: 2023-11-07→ Common Stock (3,007,890 underlying) - Exercise/Conversion
Common Stock
2023-11-07→ 96,100 totalExercise: $0.70From: 2023-10-06Exp: 2023-11-30→ Common Stock (428,571 underlying)
Footnotes (3)
- [F1]Not applicable.
- [F2]The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. Salkind has the right to convert $300,000 loan into common stock at $.70 per share or into the terms of a financing completed before November 30, 2023.
- [F3]Salkind and his trust invested an additional $1,200,000 plus converted the $300,000 principal loan plus interest of $3,495 (totaling$1,503,495) into shares of Series G Preferred Stock, convertible at holders option at any time into common stock at an effective price of $.50 per share.